



INFORMATION DISCLOSURE CITATION				ATTY. DOCKET NO. PC10607A				SERIAL NO. 09/814,442					
Use several sheets if necessary)				APPLICANT Sean Ekins									
1 or 4				FILING DATE 03/22/2001				GROUP 1614					
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
			Banks, M., et al., High throughput screening using fully integrated robotic screening. <i>J Biomolecular Screening</i> 2: 133-135, 1997										
			Bertz, R., et al., G. R.: Use of <i>in vitro</i> and <i>in vivo</i> data to estimate the likelihood of metabolic pharmacokinetic interactions. <i>Clin Pharmacokinet</i> 32: 210-258, 1997										
			Bronson, C., et al., Virtual kinetics: using statistical experimental design for rapid analysis of enzyme inhibitor mechanisms. <i>Biochem Pharmacol</i> 50: 823-831, 1995										
			Busby Jr, W., et al., Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on <i>in vitro</i> activities of cDNA-expressed human cytochromes P-450. <i>Drug Metab Dispos</i> 27: 246-249, 1999										
			Chauret, N., et al., Effect of common organic solvents on <i>in vitro</i> cytochrome P450-mediated metabolic activities in human liver microsomes. <i>Drug Metab Dispos</i> 26: 1-4, 1998										
			Crespi, C., et al., Microliter plate assays for inhibition of human drug-metabolizing cytochromes P450. <i>Anal Biochem</i> 248: 188-190, 1997										
			Crespi, C. et al., High throughput screening for inhibition of cytochrome P450 metabolism. <i>Med Chem Res</i> 8: 457-471, 1998										
			Cronin, M. T., et al, Computer-aided prediction of drug toxicity in high throughput screening. <i>Pharm Pharmacol Commun</i> 4: 157-163, 1998										
			Donato, M., et al., A microassay for measuring cytochrome P4501A1 and P4501B1 activities in intact human and rat hepatocytes cultured on 96-well plates. <i>Anal Biochem</i> 213: 29-33, 1993										
			Draper, A., et al., Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. <i>Arch Biochem Biophys</i> 341: 47-61, 1997										
			Ekins, S., et al., Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4. <i>J Pharmacol Exp Ther</i> 290: 429-438, 1999										
			Ekins, S., et al., Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6 <i>J Pharmacol Exp Ther</i> 288: 21-29, 1999b										
EXAMINER			DATE CONSIDERED										




INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) 2 or 4		ATTY. DOCKET NO. PC10607A		SERIAL NO. 09/814,442								
		APPLICANT Sean Ekins										
		FILING DATE 03/22/2001		GROUP 1614								
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
		Ekins, S., et al., Autoactivation and activation of cytochrome P450s. <i>Int J Clin Pharmacol Ther</i> 36: 642-651, 1998										
		FDA: Guidance for industry. Drug metabolism/drug interaction studies in the drug development process: studies in vitro. , 1997										
		FDA: Guidance for industry. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. , 1998										
		Fuhr, U., et al., Systematic screening for pharmacokinetic interactions during drug development. <i>Int J Clin Pharmacol Ther</i> 34: 139-151, 1996										
		Hickman, D., et al., Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. <i>Drug Metab Dispos</i> 26: 207-215, 1998										
		Hook, D.: Ultra high-throughput screening - a journey into nanoland with Gulliver and Alice. <i>Drug Discovery Today</i> 1: 267-268, 1996										
		Ito, K., et al., Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. <i>Pharmacol Rev</i> 50: 387-411, 1998										
		Korfmacher, W., et al., HPLC-API/MS/MS: a powerful tool for integrating drug metabolism into the drug discovery process. <i>Drug Discovery Today</i> 12: 532-537, 1997										
		Kronbach, T., et al. High performance liquid chromatography assays for bupropion 1'-hydroxylase, desipramine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. <i>Anal Biochem</i> 162: 24-32, 1987										
		Leeman, T., et al., Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. <i>Life Sci</i> 52: 29-34, 1992										
		Lin, J., et al., Inhibition of cytochrome P-450 and implications in drug development. <i>Ann Rep Med Chem</i> 32: 295-304, 1997										
EXAMINER		DATE CONSIDERED										



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. PC10607A				SERIAL NO. 09/814,442							
3 of 4				APPLICANT Sean Ekins				FILING DATE 03/22/2001				GROUP 1614			
U.S. PATENT DOCUMENTS															
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME			CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER							DATE	COUNTRY			CLASS	SUBCLASS	TRANSLATION		
													YES NO		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
									Lin, J., et al., Inhibition and induction of cytochrome P450 and the clinical implications. <i>Clin Pharmacokinet</i> 35: 361-390, 1998						
									Lutz, M., et al., Experimental design for high-throughput screening. <i>Drug Discovery Today</i> 1: 277-286, 1996						
									Maenpää, J., et al., Human cytochrome P4503A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective metabolism by a-naphthoflavone, terfenadine and testosterone. <i>Pharmacogenetics</i> 8, 1998						
									Miwa, G. T., et al., Goals, design, timing, and future opportunities for non clinical drug metabolism studies. <i>Toxicol Pathol</i> 23: 131-135, 1995						
									Pichard, L., et al., Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. <i>Drug Metab Dispos</i> 18: 595-606, 1990						
									Rodrigues, A., et al., Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. <i>Pharm Res</i> 14: 1504-1510, 1997						
									Rodrigues, A., et al., [O-ethyl 14C] phenacetin O-deethylase activity in human liver microsomes. <i>Drug Metab Dispos</i> 25: 1097-1100, 1997						
									Shimada, T., et al., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. <i>J Pharmacol Exp Pharmacol</i> 270: 414-423, 1994						
									Singh, J., et al., Lead development: validation and application of high throughput screening for determination of pharmacokinetic parameters for enzyme inhibitors. <i>Bioorg Med Chem</i> 4: 639-643, 1996						
									Sittampalam, G., et al., Design of signal windows in high throughput screening assays for drug discovery. <i>J Biomolecular Screening</i> 2: 159-169, 1997						
									Smith, D., et al., Human cytochrome P450s: selectivity and measurement in vivo. <i>Xenobiotica</i> 28: 1095-1128, 1998						
EXAMINER								DATE CONSIDERED							

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. PC10607A	SERIAL NO. 09/814,442
---------------------------------	---------------------------	-----------------------



(Use several sheets if necessary)

4 of 4

APPLICANT Sean Ekins

FILING DATE 03/22/2001

GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Sonderfan, A., et al., Regulation of testosterone hydroxylation by rat liver microsomal cytochrome-P450. <i>Arch Biochem Biophys</i> 255: 27-41, 1987.
	Spencer, R., High-throughput screening of historic collections: observations on file size, biological targets and file diversity. <i>Biotechnol Bioeng</i> 61: 61-67, 1998
	Tarbit, M., et al., High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. <i>Curr Opin Chem Biol</i> 2: 411-416, 1998
	Tucker, G., et al., The rational selection of drug interaction studies: implications of recent advances in drug metabolism. <i>Int J Clin Pharmacol Thera Toxicol</i> 30: 550-553, 1992
	van der Hoeven, T., et al., Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P450-reductase from rabbit liver microsomes. <i>J Biol Chem</i> 249: 6302-6310, 1974
	van der Voet, H.: Comparing the predictive accuracy of models using a simple randomization test. <i>Chem Int Lab Systems</i> 25: 313-323, 1994
	Wrighton, S., et al., The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. <i>Toxicologic Pathology</i> 23 (2): 199-208, 1995
	Wrighton, S., et al., In vitro methods for assessing human hepatic drug metabolism: their use in drug development. <i>Drug Metab Rev</i> 25 (4): 453-84, 1993
	Wynalda, M., et al., Assessment of potential interactions between dopamine agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. <i>Drug Metab Dispos</i> 25: 1211-1214, 1997

EXAMINER

DATE CONSIDERED